| Durvalumab studied in …STUDIED_INderived200 of 653show all (up to 200) |
|---|
| → studied in | NCT05712356Phase 2 · completed A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma,Malignant Bile Duct Neoplasm,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221253Phase 3 · recruiting A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04628767Phase 2/Phase 3 · recruiting Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer · 653 trials list this drug (296 active) | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04988945Phase 2 · active not recruiting TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06103864Phase 3 · recruiting A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) · 653 trials list this drug (296 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06498635Phase 3 · recruiting Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667908Phase 2 · recruiting A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890598Phase 3 · recruiting Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391670Phase 1 · recruiting A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab · 653 trials list this drug (296 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04062708Phase 2 · active not recruiting CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05061550Phase 2 · recruiting Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02484404Phase 1/Phase 2 · active not recruiting Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... · 653 trials list this drug (296 active) | — | — | Breast Neoplasm,Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04538378Phase 2 · terminated Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05696782Phase 2 · recruiting Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · 653 trials list this drug (296 active) | — | — | HER2-Negative Breast Carcinoma,Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109272Phase 2/Phase 3 · active not recruiting A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387084Phase 1 · active not recruiting Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy · 653 trials list this drug (296 active) | — | — | Malignant Skin Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06040099Phase 2 · active not recruiting A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06375915Phase 2 · recruiting Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06732401Phase 3 · active not recruiting Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06773910Phase 2 · active not recruiting BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554339Phase 3 · recruiting A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158064Phase 2 · active not recruiting Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors · 653 trials list this drug (296 active) | — | — | Germ Cell Tumor,Germinomatous Germ Cell Tumor,Dysgerminoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04105270Phase 2 · recruiting RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287775Phase 1/Phase 2 · recruiting Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195695Phase 3 · recruiting Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332351Phase 2 · not yet recruiting Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial · 653 trials list this drug (296 active) | — | — | Malignant Bladder Neoplasm,Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07459634Phase 2 · recruiting A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04462328Phase 1 · active not recruiting Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · 653 trials list this drug (296 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03847649Phase 2 · recruiting A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies · 653 trials list this drug (296 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02273375Phase 3 · completed Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · 653 trials list this drug (296 active) | — | — | Invasive Bladder Micropapillary Urothelial Carcinoma,Malignant Ureter Neoplasm,Malignant Urethral Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05403723Phase 1 · suspended Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05883644Phase 3 · active not recruiting Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282575Phase 3 · recruiting Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06503614Phase 2 · recruiting A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · 653 trials list this drug (296 active) | — | — | Non-Muscle Invasive Bladder Carcinoma,Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03775486Phase 2 · active not recruiting Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04817826Phase 2 · active not recruiting TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. · 653 trials list this drug (296 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05845450Phase 2 · recruiting Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) · 653 trials list this drug (296 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07780838Phase 2 · recruiting Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma · 653 trials list this drug (296 active) | — | — | Biliary Tract Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02962063Phase 1/Phase 2 · active not recruiting Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer · 653 trials list this drug (296 active) | — | — | Esophageal Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · 653 trials list this drug (296 active) | — | — | Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907475Phase 2 · recruiting Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial · 653 trials list this drug (296 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361395Phase 1 · active not recruiting First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05925530Phase 2 · active not recruiting Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05941897Phase 2 · active not recruiting A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06548412Phase 1/Phase 2 · recruiting CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06780137Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03937830Phase 2 · active not recruiting Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092283Phase 3 · active not recruiting Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005128Phase 3 · active not recruiting A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07361497Phase 3 · recruiting A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05198830Phase 2 · active not recruiting Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Large Cell Carcinoma,Lung Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06050252Phase 2 · suspended Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04699838Phase 2 · active not recruiting Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892953Phase 2 · recruiting Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05374603Phase 2 · active not recruiting Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691714Phase 2 · completed Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · 653 trials list this drug (296 active) | — | — | Head and Neck Neoplasm,Malignant Neoplasm,Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333678Phase 2 · terminated A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06728410Phase 2 · recruiting A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855225Phase 2 · not yet recruiting A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma · 653 trials list this drug (296 active) | — | — | Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07766187Phase 2 · not yet recruiting Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03057106Phase 2 · active not recruiting Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · 653 trials list this drug (296 active) | — | — | Carcinosarcoma,Endometrioid Adenocarcinoma,Endometrial Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04379596Phase 2 · active not recruiting Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) · 653 trials list this drug (296 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05211895Phase 3 · active not recruiting A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05298423Phase 3 · completed Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03258554Phase 2/Phase 3 · completed Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin · 653 trials list this drug (296 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03875235Phase 3 · active not recruiting Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03258593Phase 1 · completed Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) · 653 trials list this drug (296 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07531095Phase 1 · recruiting Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03682068Phase 3 · active not recruiting Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619313Phase 1 · recruiting AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer · 653 trials list this drug (296 active) | — | — | Malignant Pancreatic Neoplasm,Cholangiocarcinoma,Pancreatic Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04999969Phase 2 · active not recruiting Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06467357Phase 3 · recruiting Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965468Phase 2 · active not recruiting Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05624996Phase 3 · recruiting Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166406Phase 3 · recruiting Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03283605Phase 1/Phase 2 · completed Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas · 653 trials list this drug (296 active) | — | — | Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03847428Phase 3 · active not recruiting Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04230759Phase 2 · active not recruiting Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group · 653 trials list this drug (296 active) | — | — | Anal Carcinoma,Malignant Anal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07765433Phase 2/Phase 3 · not yet recruiting Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma,Biliary Tract Adenocarcinoma,Extrahepatic Cholangiocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05701488Phase 1 · active not recruiting SIRT With Tremelimumab and Durvalumab for Resectable HCC · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05943106Phase 3 · active not recruiting BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07759492Phase 2 · not yet recruiting Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03215095early Phase 1 · active not recruiting RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers · 653 trials list this drug (296 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068610Phase 1/Phase 2 · active not recruiting COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC · 653 trials list this drug (296 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05303532Phase 3 · enrolling by invitation Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab · 653 trials list this drug (296 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05514132Phase 1 · active not recruiting A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours · 653 trials list this drug (296 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06880523Phase 2 · recruiting STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03851614Phase 2 · active not recruiting Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors · 653 trials list this drug (296 active) | — | — | Leiomyosarcoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04269200Phase 3 · active not recruiting Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer · 653 trials list this drug (296 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137262Phase 2 · active not recruiting A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder · 653 trials list this drug (296 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05713838Phase 2 · active not recruiting Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery · 653 trials list this drug (296 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02453282Phase 3 · active not recruiting Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03706690Phase 3 · active not recruiting A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02519348Phase 2 · active not recruiting A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026062Phase 2 · completed Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 653 trials list this drug (296 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Platinum-Resistant Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03459846Phase 2 · active not recruiting A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) · 653 trials list this drug (296 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03999710Phase 2 · active not recruiting Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05170204Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215106Phase 2 · active not recruiting Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742102Phase 1/Phase 2 · active not recruiting A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer · 653 trials list this drug (296 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · 653 trials list this drug (296 active) | — | — | Low Grade Fallopian Tube Serous Adenocarcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Seromucinous Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06960577Phase 3 · recruiting Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) · 653 trials list this drug (296 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556773Phase 1 · active not recruiting A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer · 653 trials list this drug (296 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06124118Phase 1 · withdrawn Tumor Treating Fields for Locally Advanced NSCLC · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02888743Phase 2 · active not recruiting Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Colorectal Neoplasm,Lung Non-Small Cell Carcinoma,Colorectal Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03011814Phase 1/Phase 2 · recruiting Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma · 653 trials list this drug (296 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mycosis Fungoides,Sezary Syndrome+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03842228Phase 1 · active not recruiting Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations · 653 trials list this drug (296 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06963346Phase 1 · recruiting Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents · 653 trials list this drug (296 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05632809Phase 2 · recruiting REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05771480Phase 3 · active not recruiting Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03141359Phase 2 · active not recruiting Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03581487Phase 1/Phase 2 · completed Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710223Phase 1 · active not recruiting Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339059Phase 2 · recruiting Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03298451Phase 3 · active not recruiting Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04612751Phase 1 · active not recruiting Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06992609Phase 3 · active not recruiting Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04053322Phase 2 · active not recruiting Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04163432Phase 2 · terminated Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04521686Phase 1 · active not recruiting Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations · 653 trials list this drug (296 active) | — | — | Chondrosarcoma,Glioma,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07720284Phase 3 · recruiting An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04918186Phase 2 · recruiting Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer · 653 trials list this drug (296 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07718139active not recruiting Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03833154Phase 3 · active not recruiting Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05194293Phase 2 · active not recruiting Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03732677Phase 3 · active not recruiting Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC · 653 trials list this drug (296 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04395079Phase 2 · active not recruiting Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies · 653 trials list this drug (296 active) | — | — | Malignant Female Reproductive System Neoplasm,Platinum-Resistant Malignant Female Reproductive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07710885Phase 3 · recruiting Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03043872Phase 3 · active not recruiting Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075527Phase 2 · terminated A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · 653 trials list this drug (296 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03148327Phase 1/Phase 2 · terminated Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05640791Phase 2 · recruiting Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer · 653 trials list this drug (296 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03317158Phase 1/Phase 2 · active not recruiting Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder · 653 trials list this drug (296 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03778957Phase 3 · active not recruiting A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02516241Phase 3 · active not recruiting Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02734004Phase 1/Phase 2 · active not recruiting A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. · 653 trials list this drug (296 active) | — | — | Malignant Gastric Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03519971Phase 3 · completed Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05301842Phase 3 · active not recruiting Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05450692Phase 3 · active not recruiting A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06112379Phase 3 · active not recruiting A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer · 653 trials list this drug (296 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03942328Phase 1/Phase 2 · recruiting Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma,Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04711824Phase 1/Phase 2 · active not recruiting Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases · 653 trials list this drug (296 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05411094Phase 1 · active not recruiting Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer · 653 trials list this drug (296 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07625930Phase 2 · not yet recruiting RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial · 653 trials list this drug (296 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07174583Phase 1/Phase 2 · recruiting A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Neuroendocrine Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04905316Phase 2 · completed A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03528694Phase 3 · active not recruiting Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737643Phase 3 · active not recruiting Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients · 653 trials list this drug (296 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585477Phase 2 · suspended Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06117891active not recruiting An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06824363early Phase 1 · recruiting ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu · 653 trials list this drug (296 active) | — | — | Adult Solid Neoplasm,Malignant Solid Neoplasm,Esophageal Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745689Phase 2 · active not recruiting Study of AZD2811 + Durvalumab in ES-SCLC · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06008093Phase 2 · active not recruiting A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06630130Phase 2 · recruiting Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer · 653 trials list this drug (296 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04294498Phase 2 · completed Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05136846Phase 1 · recruiting Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191250Phase 2 · terminated --SuPERIOR Trial-- · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05557838Phase 3 · active not recruiting Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07149363Phase 2 · recruiting Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07672223Phase 3 · not yet recruiting A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03529422Phase 2 · active not recruiting Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN · 653 trials list this drug (296 active) | — | — | Malignant Lip and Oral Cavity Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03991832Phase 2 · active not recruiting Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors · 653 trials list this drug (296 active) | — | — | Solid Neoplasm,Glioma,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04522544Phase 2 · active not recruiting Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04668300Phase 2 · active not recruiting Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma · 653 trials list this drug (296 active) | — | — | Osteosarcoma,Dedifferentiated Liposarcoma,Angiosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768570Phase 2 · active not recruiting Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer · 653 trials list this drug (296 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05221840Phase 3 · active not recruiting A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05683977active not recruiting A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02671435Phase 1/Phase 2 · active not recruiting A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors · 653 trials list this drug (296 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05629585Phase 3 · active not recruiting A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) · 653 trials list this drug (296 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02726997Phase 1/Phase 2 · active not recruiting Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) · 653 trials list this drug (296 active) | — | — | Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03003962Phase 3 · active not recruiting Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04106115Phase 1/Phase 2 · recruiting DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr · 653 trials list this drug (296 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04728230Phase 1/Phase 2 · active not recruiting Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07146230Phase 2 · not yet recruiting The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637513Phase 3 · not yet recruiting Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01993810Phase 3 · active not recruiting Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04748419Phase 1/Phase 2 · terminated Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab · 653 trials list this drug (296 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04960709Phase 3 · active not recruiting Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin · 653 trials list this drug (296 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04513925Phase 3 · completed A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03257761Phase 1 · active not recruiting Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06680739Phase 2 · recruiting Single cEll pRofiling PErsistaNce To ImmuNothErapy · 653 trials list this drug (296 active) | — | — | Malignant Colorectal Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03237377Phase 2 · terminated Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216290Phase 2 · active not recruiting A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial · 653 trials list this drug (296 active) | — | — | Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05043090Phase 3 · active not recruiting Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC · 653 trials list this drug (296 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06551142Phase 1 · recruiting A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) · 653 trials list this drug (296 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06954480Phase 2 · recruiting Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer · 653 trials list this drug (296 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06898957Phase 1 · active not recruiting Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) · 653 trials list this drug (296 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04380636Phase 3 · active not recruiting Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) · 653 trials list this drug (296 active) | — | — | Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05255653Phase 2/Phase 3 · recruiting Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features · 653 trials list this drug (296 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06606847Phase 2 · active not recruiting A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06591650Phase 2 · recruiting Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer · 653 trials list this drug (296 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550260Phase 3 · active not recruiting Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC · 653 trials list this drug (296 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058663Phase 1 · recruiting Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma · 653 trials list this drug (296 active) | — | — | Intrahepatic Cholangiocarcinoma,Oligometastatic Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07012798Phase 2 · recruiting FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03819465Phase 1 · active not recruiting A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC · 653 trials list this drug (296 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07081633Phase 2 · active not recruiting Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma · 653 trials list this drug (296 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |